Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (30148)	1/12/2000 11:11:00 AM
From: Richard Belanger	Read Replies (2) \| Respond to of 32384

Henry - Which type and stage of NHL are we talking about? (Guess I should read the protocol.) For low-grade B-cell NHL, ONTAK would face increasing competition from newer approved treatments such as IDEC's Rituxan, and likey-to-be approved radioimmunotherapies such as Coulter's Bexxar and IDEC's Zevalin. Then of course there are the conventional therapies. Eventually, most patients become refractory to these and new therapies would be indicated. This is a large market. BTW, Torben, I hope you will take pity on the unrefined and serve something other than single malt at the party. A simple Chardonnay or even a Sam Adams would be just great. Rich